基于前列腺特异性膜抗原的18F-DCFPyL引导冷冻消融治疗11C-胆碱PET/CT认为更广泛转移患者的单个阳性病灶
一名72岁前列腺癌患者(Gleason 5+4,PSA 7.9 ng/mL)行根治性前列腺切除及淋巴结清扫,放疗后3年出现PSA升高至1.08 ng/mL。经PSMA 18F-DCFPyL PET/CT、常规CT、18F-FDG PET/CT和11C-胆碱PET/CT评估,PSMA 18F-DCFPyL PET/CT成功靶向寡转移病灶,而其他影像学检查对疾病范围的评估不正确。
要点
- PSMA 18F-DCFPyL PET/CT成功靶向寡转移性前列腺癌病灶。
- 常规CT、18F-FDG PET/CT和11C-胆碱PET/CT对疾病范围评估不正确。
- 基于特定放射性示踪剂的PET/CT引导干预有望检测其他影像方法显示不佳的摄病灶。
核心结论
- PSMA 18F-DCFPyL PET/CT成功靶向寡转移性前列腺癌,而其他影像学检查对疾病范围的评估不正确。
研究设计与样本
- 病例报告:一名72岁男性前列腺癌患者,初始Gleason评分5+4,PSA 7.9 ng/mL,行根治性前列腺切除术和淋巴结清扫。
主要发现
- 放疗后3年,6个月内观察到PSA升高,PSA水平达到1.08 ng/mL。
- 患者接受了PSMA 18F-DCFPyL PET/CT、常规CT、18F-FDG PET/CT和11C-胆碱PET/CT评估。
- PSMA 18F-DCFPyL PET/CT成功靶向寡转移性前列腺癌,而其他影像学检查对疾病范围的评估不正确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET/CT-guided interventions using specific radiotracers are promising for detecting avid lesions not well visualized with other imaging methods. A 72-year-old man who initially presented with prostate cancer Gleason 5 + 4 (prostate-specific antigen [PSA] = 7.9 ng/mL) underwent radical prostatectomy and node dissection. Three years after radiation, a rising PSA was observed over 6 months with PSA level reaching 1.08 ng/mL. He was evaluated with prostate-specific membrane antigen-based (PSMA) F-DCFPyL PET/CT, conventional CT, F-FDG PET/CT, and C-choline PET/CT. The PSMA F-DCFPyL PET/CT successfully targeted oligometastatic prostate cancer, whereas the other imaging studies were not correct in assessing disease extent.
引用
- Cornelis FH, Durack JC, Morris MJ, et al. Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT. Clin Nucl Med. 2017. PMID: 29099733. doi:10.1097/RLU.0000000000001846
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。